Citations (61)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Andrea Carlo Rossetti, Maria Serena Paladini, Giorgio Racagni, Marco Andrea Riva, Annamaria Cattaneo & Raffaella Molteni. (2018) Genome-wide analysis of LPS-induced inflammatory response in the rat ventral hippocampus: Modulatory activity of the antidepressant agomelatine. The World Journal of Biological Psychiatry 19:5, pages 390-401.
Read now
Read now
Elena Guerini, Simone Schadt, Gerard Greig, Ruth Haas, Christophe Husser, Manfred Zell, Christoph Funk, Thomas Hartung, Andreas Gloge & Navita L. Mallalieu. (2017) A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]-basimglurant and absolute bioavailability after oral administration and concomitant intravenous microdose administration of [13C6]-labeled basimglurant in humans. Xenobiotica 47:2, pages 144-153.
Read now
Read now
Michael Thase, Yuko Asami, Dalia Wajsbrot, Kathleen Dorries, Matthieu Boucher & Elizabeth Pappadopulos. (2017) A meta-analysis of the efficacy of venlafaxine extended release 75–225 mg/day for the treatment of major depressive disorder. Current Medical Research and Opinion 33:2, pages 317-326.
Read now
Read now
Colin G. Rousseaux & Stephanie F. Greene. (2016) Sigma receptors [σRs]: biology in normal and diseased states. Journal of Receptors and Signal Transduction 36:4, pages 327-388.
Read now
Read now
Zheng-Yi Zhou, Shawn Sun, Pooja Chopra, Yichen Zhong, Todor Totev & James Signorovitch. (2015) Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder. Journal of Medical Economics 18:11, pages 919-929.
Read now
Read now
Daniel Martins-de-Souza. (2014) Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder. Dialogues in Clinical Neuroscience 16:1, pages 63-73.
Read now
Read now
Paul A Keedwell & Allan H Young. (2014) Emerging drugs for bipolar depression: an update. Expert Opinion on Emerging Drugs 19:1, pages 25-36.
Read now
Read now
Paola Salvatore, Premananda Indic, Greg Murray & Ross J. Baldessarini. (2012) Biological rhythms and mood disorders. Dialogues in Clinical Neuroscience 14:4, pages 369-379.
Read now
Read now
Articles from other publishers (53)
Seema Mehdi, Shahid Ud Din Wani, K.L. Krishna, Nabeel Kinattingal & Tamsheel Fatima Roohi. (2023) A review on linking stress, depression, and insulin resistance via low-grade chronic inflammation. Biochemistry and Biophysics Reports 36, pages 101571.
Crossref
Crossref
Christiane Brandwein, Cathalijn H.C. Leenaars, Laura Becker, Natascha Pfeiffer, Ana-Maria Iorgu, Melissa Hahn, Gaia A. Vairani, Lars Lewejohann, André Bleich, Anne S. Mallien & Peter Gass. (2023) A systematic mapping review of the evolution of the rat Forced Swim Test: Protocols and outcome parameters. Pharmacological Research 196, pages 106917.
Crossref
Crossref
Umberto Albert, Carmine Tomasetti, Camillo Marra, Francesca Neviani, Alessandro Pirani, Daiana Taddeo, Orazio Zanetti & Giuseppe Maina. (2023) Treating depression in clinical practice: new insights on the multidisciplinary use of trazodone. Frontiers in Psychiatry 14.
Crossref
Crossref
Stefano Farioli-Vecchioli & Debora Cutuli. 2023. Neurobiological and Psychological Aspects of Brain Recovery. Neurobiological and Psychological Aspects of Brain Recovery
253
287
.
Adem T. Can, Daniel F. Hermens & Jim Lagopoulos. (2022) A unique case of very low‐dose subcutaneous ketamine use: Maintenance option of ketamine for treatment‐resistant depression. Clinical Case Reports 10:12.
Crossref
Crossref
Julio Rodríguez-Lavado, Jazmín Alarcón-Espósito, Michael Mallea & Alejandro Lorente. (2022) A New Paradigm Shift in Antidepressant Therapy: From Dual-action
to Multitarget-directed Ligands. Current Medicinal Chemistry 29:29, pages 4896-4922.
Crossref
Crossref
Francisco López-Muñoz, Pilar D’Ocón, Alejandro Romero, José A Guerra & Cecilio Álamo. (2022) Role of serendipity in the discovery of classical antidepressant drugs: Applying operational criteria and patterns of discovery. World Journal of Psychiatry 12:4, pages 588-602.
Crossref
Crossref
Yue Ma, Estrella Frutos-Beltrán, Dongwei Kang, Christophe Pannecouque, Erik De Clercq, Luis Menéndez-Arias, Xinyong Liu & Peng Zhan. (2021) Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chemical Society Reviews 50:7, pages 4514-4540.
Crossref
Crossref
Sarah Delcourte, Adeline Etievant & Nasser Haddjeri. 2021. 5-HT Interaction with Other Neurotransmitters: Experimental Evidence and Therapeutic Relevance - Part A. 5-HT Interaction with Other Neurotransmitters: Experimental Evidence and Therapeutic Relevance - Part A
7
81
.
Kylie O'Brien & Philip BlairKylie O’Brien & Philip Blair. 2021. Medicinal Cannabis and CBD in Mental Healthcare. Medicinal Cannabis and CBD in Mental Healthcare
195
252
.
Luca Carnevali, Rosario Statello, Federica Vacondio, Francesca Ferlenghi, Gilberto Spadoni, Silvia Rivara, Marco Mor & Andrea Sgoifo. (2020) Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats. European Neuropsychopharmacology 32, pages 77-87.
Crossref
Crossref
Kaipuzha Venu Athira, Sikta Bandopadhyay, Pavan Kumar Samudrala, V.G.M. Naidu, Mangala Lahkar & Sumana Chakravarty. (2020) An Overview of the Heterogeneity of Major Depressive Disorder: Current Knowledge and Future Prospective. Current Neuropharmacology 18:3, pages 168-187.
Crossref
Crossref
Jihye Kim, Eunji Cha, Woo Kyu Park, Hye Yeon Lee, Sang Min Lim, Hak Joong Kim & Ae Nim Pae. (2020) Evaluation of anti-depressant effects of phthalazinone-based triple-acting small molecules against 5-HT2A, 5-HT2C, and the serotonin transporter. Bioorganic & Medicinal Chemistry Letters 30:4, pages 126882.
Crossref
Crossref
Veni Bharti, Hua Tan, Jaspreet Deol, Zijian Wu & Jun-Feng Wang. (2019) Upregulation of antioxidant thioredoxin by antidepressants fluoxetine and venlafaxine. Psychopharmacology 237:1, pages 127-136.
Crossref
Crossref
Ilya D. Ionov, Irina I. Pushinskaya, Niсholas P. Gorev & David D. Frenkel. (2019) Antidepressants upregulate c-Fos expression in the lateral entorhinal cortex and hippocampal dorsal subiculum: Study in rats. Brain Research Bulletin 153, pages 102-108.
Crossref
Crossref
Kr. Roversi, Caren Tatiane de David Antoniazzi, L. H. Milanesi, H. Z. Rosa, M. Kronbauer, D. R. Rossato, T. Duarte, M. M. Duarte & Marilise E. Burger. (2019) Tactile Stimulation on Adulthood Modifies the HPA Axis, Neurotrophic Factors, and GFAP Signaling Reverting Depression-Like Behavior in Female Rats. Molecular Neurobiology 56:9, pages 6239-6250.
Crossref
Crossref
John F. Kelly, Lauren Hoffman, Corrie Vilsaint, Roger Weiss, Andrew Nierenberg & Bettina Hoeppner. (2019) Peer support for mood disorder: Characteristics and benefits from attending the Depression and Bipolar Support Alliance mutual-help organization. Journal of Affective Disorders 255, pages 127-135.
Crossref
Crossref
Parashar Ramanuj, Erin K Ferenchick & Harold Alan Pincus. (2019) Depression in primary care: part 2—management. BMJ, pages l835.
Crossref
Crossref
Deanna M. Barch, David Pagliaccio, Katherine Luking, Erin K. Moran & Adam J. Culbreth. 2019. Emotion in the Mind and Body. Emotion in the Mind and Body
121
160
.
Hong Gong, Wen-Jun Su, Zhi-Yong Cao, Yong-Jie Lian, Wei Peng, Yun-Zi Liu, Yi Zhang, Lin-Lin Liu, Ran Wu, Bo Wang, Ting Zhang, Yun-Xia Wang & Chun-Lei Jiang. (2018) Hippocampal Mrp8/14 signaling plays a critical role in the manifestation of depressive-like behaviors in mice. Journal of Neuroinflammation 15:1.
Crossref
Crossref
Yan-Jiao Li, Yu-Jiao Li, Liu-Di Yang, Kun Zhang, Kai-Yin Zheng, Xin-Miao Wei, Qi Yang, Wen-Min Niu, Ming-Gao Zhao & Yu-Mei Wu. (2018) Silibinin exerts antidepressant effects by improving neurogenesis through BDNF/TrkB pathway. Behavioural Brain Research 348, pages 184-191.
Crossref
Crossref
Catherine E. Prado, Stephanie Watt & Simon F. Crowe. (2018) A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychology Review 28:1, pages 32-72.
Crossref
Crossref
Deanna M. Barch, David Pagliaccio & Katherine R. Luking. 2018. Neurobiology of Abnormal Emotion and Motivated Behaviors. Neurobiology of Abnormal Emotion and Motivated Behaviors
278
304
.
Hong-Yan Li, Ying-Hua Zhao, Min-Jie Zeng, Fang Fang, Min Li, Ting-Ting Qin, Lu-Yu Ye, Hong-Wei Li, Rong Qu & Shi-Ping Ma. (2017) Saikosaponin D relieves unpredictable chronic mild stress induced depressive-like behavior in rats: involvement of HPA axis and hippocampal neurogenesis. Psychopharmacology 234:22, pages 3385-3394.
Crossref
Crossref
Tadesse Melaku Abegaz, Lamessa Melese Sori & Hussien Nurahmed Toleha. (2017) Self-Reported Adverse Drug Reactions, Medication Adherence, and Clinical Outcomes among Major Depressive Disorder Patients in Ethiopia: A Prospective Hospital Based Study. Psychiatry Journal 2017, pages 1-8.
Crossref
Crossref
Stephen Fowler, Elena Guerini, NaHong Qiu, Yumi Cleary, Neil Parrott, Gerard Greig & Navita L. Mallalieu. (2017) Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non–Michaelis-Menten P450 Kinetics on Fraction Metabolized. Journal of Pharmacology and Experimental Therapeutics 360:1, pages 164-173.
Crossref
Crossref
Sidney H. KennedyRaymond W. LamRoger S. McIntyre, S. Valérie Tourjman, Venkat Bhat, Pierre Blier, Mehrul Hasnain, Fabrice Jollant, Anthony J. Levitt, Glenda M. MacQueen, Shane J. McInerney, Diane McIntosh, Roumen V. Milev, Daniel J. Müller, Sagar V. Parikh, Norma L. Pearson, Arun V. Ravindran & Rudolf Uher. (2016) Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. The Canadian Journal of Psychiatry 61:9, pages 540-560.
Crossref
Crossref
Faryal Mallick & Cheryl B. McCullumsmith. (2016) Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior. Current Psychiatry Reports 18:6.
Crossref
Crossref
Bart Ellenbroek & Jiun Youn. 2016. Gene-Environment Interactions in Psychiatry. Gene-Environment Interactions in Psychiatry
173
231
.
Mitsumasa Kurita, Aintzane García-Bea & Javier González-Maeso. 2016. The Medical Basis of Psychiatry. The Medical Basis of Psychiatry
601
654
.
Mark J. Millan, Guy M. Goodwin, Andreas Meyer-Lindenberg & Sven Ove Ögren. (2015) Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. European Neuropsychopharmacology 25:5, pages 599-656.
Crossref
Crossref
Mark J. Millan, Guy M. Goodwin, M. Hamon, Andreas Meyer-Lindenberg & Sven Ove Ögren. (2015) 60 years of advances in neuropsychopharmacology for improving brain health, renewed hope for progress. European Neuropsychopharmacology 25:5, pages 591-598.
Crossref
Crossref
Francesc Artigas. (2015) Developments in the field of antidepressants, where do we go now?. European Neuropsychopharmacology 25:5, pages 657-670.
Crossref
Crossref
Olivia F. O’Leary, Timothy G. Dinan & John F. Cryan. (2015) Faster, better, stronger: Towards new antidepressant therapeutic strategies. European Journal of Pharmacology 753, pages 32-50.
Crossref
Crossref
Basant Pradhan, Tapan Parikh, Ramkrishna Makani & Madhusmita Sahoo. (2015) Ketamine, Transcranial Magnetic Stimulation, and Depression Specific Yoga and Mindfulness Based Cognitive Therapy in Management of Treatment Resistant Depression: Review and Some Data on Efficacy. Depression Research and Treatment 2015, pages 1-14.
Crossref
Crossref
Vincenzo Micale, Katarina Tabiova, Jana Kucerova & Filippo Drago. 2015. Cannabinoid Modulation of Emotion, Memory, and Motivation. Cannabinoid Modulation of Emotion, Memory, and Motivation
97
129
.
Deanna M. Barch, David Pagliaccio & Katherine Luking. 2016. Behavioral Neuroscience of Motivation. Behavioral Neuroscience of Motivation
411
449
.
Elizabeth Brunner, Mauricio Tohen, Olawale Osuntokun, John Landry & Michael E Thase. (2014) Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology 39:11, pages 2549-2559.
Crossref
Crossref
Mark J. Millan. (2013) On ‘polypharmacy’ and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal. The International Journal of Neuropsychopharmacology 17:07, pages 1009-1037.
Crossref
Crossref
Lauren Jacobson. 2011. Comprehensive Physiology. Comprehensive Physiology
715
738
.
James A Cooper, Vivian L Tucker & George I Papakostas. (2013) Resolution of sleepiness and fatigue: A comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. Journal of Psychopharmacology 28:2, pages 118-124.
Crossref
Crossref
Meghan M. Grady & Stephen M. Stahl. (2013) Novel agents in development for the treatment of depression. CNS Spectrums 18:s1, pages 34-41.
Crossref
Crossref
Jens-Uwe Peters. (2013) Polypharmacology – Foe or Friend?. Journal of Medicinal Chemistry 56:22, pages 8955-8971.
Crossref
Crossref
Snjezana Lelas, Yu-Wen Li, Tanya L. Wallace-Boone, Matthew T. Taber, Amy E. Newton, Rick L. Pieschl, Carl D. Davis, Thaddeus F. Molski, Kimberly S. Newberry, Michael F. Parker, Kevin W. Gillman, Joanne J. Bronson, John E. Macor & Nicholas J. Lodge. (2013) NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the Gerbil forced swim test. Neuropharmacology 73, pages 232-240.
Crossref
Crossref
Vincenzo Micale, Jana Kucerova & Alexandra Sulcova. (2013) Leading compounds for the validation of animal models of psychopathology. Cell and Tissue Research 354:1, pages 309-330.
Crossref
Crossref
Adriana Medina, Sharon Burke, Robert C. Thompson, William BunneyJr.Jr., Richard. M. Myers, Alan Schatzberg, Huda Akil & Stanley J. Watson. (2013) Glutamate transporters: A key piece in the glutamate puzzle of major depressive disorder. Journal of Psychiatric Research 47:9, pages 1150-1156.
Crossref
Crossref
Jeffrey Cummings & Dag Aarsland. 2013. Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders. Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders
285
291
.
. 2013. Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders. Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders
255
291
.
Adrian L. Lopresti, Sean D. Hood & Peter D. Drummond. (2013) A review of lifestyle factors that contribute to important pathways associated with major depression: Diet, sleep and exercise. Journal of Affective Disorders 148:1, pages 12-27.
Crossref
Crossref
Vincenzo Micale, Vincenzo Di Marzo, Alexandra Sulcova, Carsten T. Wotjak & Filippo Drago. (2013) Endocannabinoid system and mood disorders: Priming a target for new therapies. Pharmacology & Therapeutics 138:1, pages 18-37.
Crossref
Crossref
Renan Rocha, Joel Rennó Jr, Hewdy Lobo Ribeiro, Amaury Cantilino, Jerônimo de Almeida Mendes Ribeiro, Renata Demarque, Juliana Pires Cavalsan, Gislene Cristina Valadares & Antonio Geraldo da Silva. (2013) Tratamento da Depressão no Climatério. Debates em Psiquiatria 3:1, pages 18-25.
Crossref
Crossref
A.L. Lussier, R. Romay-Tall?n, H.J. Caruncho & L.E. Kalynchuk. (2013) Altered GABAergic and glutamatergic activity within the rat hippocampus and amygdala in rats subjected to repeated corticosterone administration but not restraint stress. Neuroscience 231, pages 38-48.
Crossref
Crossref
Michael W. Rabow & Michael Xiang Lee. (2012) Palliative Care in Castrate-Resistant Prostate Cancer. Urologic Clinics of North America 39:4, pages 491-503.
Crossref
Crossref